Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies (Q36273691)

13 August 2017

1 reference

title

Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies (English)

1 reference

13 August 2017

1 reference

Robert M Prins

2

0 references

Linda Liau

1 reference

ORCID Public Data File 2021

author name string

Haumith R Khan-Farooqi

series ordinal

1

1 reference

13 August 2017

Linda M Liau

series ordinal

3

1 reference

13 August 2017

publication date

1 October 2005

1 reference

13 August 2017

published in

Neurological Research

1 reference

13 August 2017

volume

27

1 reference

13 August 2017

issue

7

1 reference

13 August 2017

page(s)

692-702

1 reference

Decoding the patterns of self and nonself by the innate immune system

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Immunology and immunotherapy in neurosurgical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Danger signals: a time and space continuum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

CpG motif acts as a 'danger signal' and provides a T helper type 1-biased microenvironment for DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Innate immunity: the missing link in neuroprotection and neurodegeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Transplantation immunology and the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

AIM-2: a novel tumor antigen is expressed and presented by human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Gene expression profiling identifies molecular subtypes of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Identification of molecular subtypes of glioblastoma by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Linking genomics to immunotherapy by reverse immunology--'immunomics' in the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Gene expression profiling of gliomas strongly predicts survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Robustness of gene expression profiling in glioma specimen samplings and derived cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Identification of human tumor antigens and its implications for diagnosis and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Strategies using the immune system for therapy of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Targeted toxin therapy for malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Cytokine gene therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

CpG motifs are efficient adjuvants for DNA cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

Listeria-based cancer vaccines that segregate immunogenicity from toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164105X49490

21 January 2018

Identifiers

DOI

10.1179/016164105X49490

1 reference

13 August 2017

1 reference